HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

And the discovery could soon lead to personalized treatments for ... Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML ...

When she first stepped into urgent care in early December, Maggie O'Neil wondered whether her unaccounted-for bruises and fatigue were worth the wait for a clinician. "I thought I had low iron or ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in development may improve outcomes. This cancer ...

equitable care strategies and tailored treatment approaches. An analysis of the National Cancer Database showed that patients aged 80 years and older diagnosed with acute myeloid leukemia (AML) face ...

Leukemia symptoms can vary by the cancer stage and type of leukemia you have. In the early stages, leukemia symptoms like fatigue, fever, and bruising can be subtle and easily dismissed. But, as the ...

Boston – Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute ... graft versus leukemia ...